Trials / Completed
CompletedNCT00637182
Gynecomastia Extension Study
An OptioExtension of Trial 1033US/0006 to Assess Safety, Tolerability, Efficacy of Anastrozole (ZD1033, Arimidex™) in Treatment of Gynecomastia in Pubertal Boys Given Placebo and to Conduct a Long-Term Safety Follow-Up of Non-Responding Subjects Given Anastrozole in the Previous Trial
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- AstraZeneca · Industry
- Sex
- Male
- Age
- 11 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to look at the effect of anastrozole (ZD1033, Arimidex™) in reducing gynecomastia in pubertal boys treated with placebo in Trial 1033US/0006 (another anastrozole study).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anastrozole |
Timeline
- Start date
- 2001-01-01
- Primary completion
- 2002-06-01
- Completion
- 2002-10-01
- First posted
- 2008-03-17
- Last updated
- 2008-03-17
Source: ClinicalTrials.gov record NCT00637182. Inclusion in this directory is not an endorsement.